Table E3. Contd Biomarker-low Biomarker-high† Placebo Tralokinumab Tralokinumab Tralokinumab Placebo Tralokinumab Tralokinumab Tralokinumab 45 mg 45 mg 150 mg 300 mg 150 mg 300 mg 29 26 20 25 21 23 31 26 IgE, n EASI, n (week 12) 25 21 18 22 14 22 26 25 Adjusted change in EASI, (1.50) (1.69) (1.52) (2.69) (2.32) (2.04) (2.17) –10.82 –15.18 –16.02 –13.85 –10.55 –12.17 –15.04 –16.63 mean (SE) (1.40) Adjusted mean difference - (–8.44 (–9.55 (–7.15 - (–8.70 (–11.18 (–12.95 –4.36 –5.19 –3.03 –1.62 –4.49 –6.08 to to to 1.09) to 5.45) to 2.20) to 0.79) –0.29)‡ –0.84)‡ (95% CI) IGA, n (week 12) 29 26 20 24 20 23 31 26 IGA responders*, n (adj %) 6 (20.2) 5 (20.1) 6 (27.5) 7 (30.9) 0 1 (4.3) 4 (12.9) 5 (19.2)
Table E3. Contd Biomarker-low Biomarker-high† Placebo Tralokinumab 45 mg Tralokinumab 150 mg Tralokinumab 300 mg Placebo Tralokinumab 45 mg Tralokinumab 150 mg Tralokinumab 300 mg IgE, n 29 26 20 25 21 23 31 26 EASI, n (week 12) 25 21 18 22 14 22 26 25 Adjusted change in EASI, mean (SE) –10.82 (1.40) –15.18 (1.50) –16.02 (1.69) –13.85 (1.52) –10.55 (2.69) –12.17 (2.32) –15.04 (2.04) –16.63 (2.17) Adjusted mean difference (95% CI) - –4.36 (–8.44 to –0.29)‡ –5.19 (–9.55 to –0.84)‡ –3.03 (–7.15 to 1.09) - –1.62 (–8.70 to 5.45) –4.49 (–11.18 to 2.20) –6.08 (–12.95 to 0.79) IGA, n (week 12) 29 26 20 24 20 23 31 26 IGA responders*, n (adj %) 6 (20.2) 5 (20.1) 6 (27.5) 7 (30.9) 0 1 (4.3) 4 (12.9) 5 (19.2)
1-s2.0-S0091674918308509-mmc1.docx